An incidence model of the cost of advanced prostate cancer in Spain

Journal of Medical Economics

Volumn 17, Issue 2, 2014, Pages 125-131

  Hart, W M ^a   Nazir, J ^b   Baskin Bey, E ^b  

^a Health Economics   (United Kingdom)

^b ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

Author keywords

Advanced PCa; Incidence model; Lifetime costs

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; INCIDENCE; LIFESPAN; MALE; PROSTATE CANCER; SPAIN;

COSTS AND COST ANALYSIS; DISEASE PROGRESSION; HEALTH SERVICES; HUMANS; INCIDENCE; MALE; MODELS, ECONOMIC; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SEER PROGRAM; SPAIN; SURVIVAL ANALYSIS;

EID: 84892718834     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.877020     Document Type: Article

References (24)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8
2. Cozar JM, Miñ ana BF, Gó mez-Veiga F, et al. Prostate cancer incidence and newly-diagnosed patient profile in Spain in 2010. BJU Int 2012;110:E701-6
3. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92
4. Neppl-Huber C, Zappa M, Coebergh JW, et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol 2012;23:1325-34
5. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92
6. Cayuela A, Rodŕguez-Doḿnguez S, Vigil-Mart́n E, et al. Cambios recientes en la mortalidad por cá ncer de pró stata en Españ a: estudio de tendencias en el periodo 1991-2005. Actas Urol Esp 2008;32:184-9
7. Fourcade RO, Benedict A, Black LK, et al. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK. BJU Int 2009;105:49-56
8. Stokes ME, Ishak J, Proskorovosky I, et al. Lifetime economic burden of prostate cancer. BMC Health Services Res 2011;11:349
9. Krahn MD, Zagorski B, Laporte A, et al. Healthcare costs associated with Prostate cancer: estimates from a population-based study. BJU Int 2009;105:338-46
10. Sá nchez MJ, Payer T, De Angelis R, et al. Cancer incidence and mortality in Spain: estimates and projections for the period 1981-2012. Ann Oncol 2010;21(3 Suppl):ii30-6
11. Roazzi P, Capocaccia R, Santaquilani M, et al. Electronic availability of EUROCARE-3 data: a tool for further analysis. Ann Oncol 2003;14:150-5
12. Coleman MP, Gatta G, Verdecchia A, et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003;14(5 Suppl):128-49
13. Instituto Nacional de Estad́stica. Indice de precios al consume. Madrid. 2012. http://www.ine.es/varipc/index.do. Accessed March 24, 2013
14. Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of Prostate cancer treatments. Cancer 2007;109:518-27
15. Roehrborn C, Black L. The economic burden of prostate cancer. BJUI 2011;108:806-13
16. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630-41
17. Instituto Nacional de Estad́stica. Tablas de mortalidad de la población de Españ a 1991-2011. Madrid. 2012. http://www.ine.es/ jaxi/tabla.do?path /t20/p319a/serie/l0/&file01001.px&typepcaxis&L0. Accessed March 14, 2013
18. Brenner H, Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol 2005;23:441-7
19. Schoenstadt A. Prostate cancer prognosis. Progress for stage III prostate cancer. http://prostate-cancer.emedtv.com/prostate-cancer/prostate- cancerprognosis-p2.html. Accessed March 14, 2013
20. Ló pez Bastida J, Oliva J, Antoñ anzas F, et al. Propuesta de gu?á para la evaluació n econó mica aplicada a las tecnolog?ás sanitarias. Gac Sanit 2010;24:154-70
21. Larrañ aga N, Galcerá n J, Ardanaz E, et al. Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality. Ann Oncol 2010;21(Suppl 3):iii83-9
22. Osanto S, Van Poppel H. Emerging novel therapies for advanced prostate cancer. Therapeut Adv Urol 2012;4:3-12
23. Becerra Bachino V, Cots F, Guedea F, et al. Cost comparison of three treatments for localized prostate cancer in Spain: radical prostatectomy, prostate brachytherapy and external 3D conformal radiotherapy. Gac Sanit 2011;25:35-43
24. Sanyal C, Aprikian AG, Chevalier S, et al. Direct cost for initial management of prostate cancer: a systematic review. Curr Oncol 2013;20:e522-31